clinical photodynamic therapy (PDT) applications are included. This reflects the fact that we are moving beyond the empirical use of PDT to a stage in which more sophisticated dosimetry and monitoring techniques are being investigated, and much work is being done to improve our understanding of the basic mechanisms involved. In this spirit, we open with an excellent treatise by Wilson et al, who discuss the use of photosensitizer fluorescence measurements to monitor photobleaching mechanisms and tissue sensitizer levels, and propose a strategy for their use in improving light dosimetry. (The potential use of such fluorescence measurements was also addressed in the first IPA issue by Braichotte et al.) The diagnostic potential of fluorescence imaging is well known, and three papers address potential improvements to such imaging methods. Cubeddu et al show that time-gating can improve tumour-normal tissue contrast. Mizeret et al present a technique for imaging fluorescence lifetime, which promises to further improve this contrast. An in vitro fluorescence imaging study by Ismail et al looks deeper into biochemical effects on aminolaevulinic acid (ALA)-induced fluorescence in cultured tumour and non-tumour tissues.
